Distribution Finance Capital Holdings plc, a niche lender providing working capital solutions to dealers and manufacturers across the UK, today announces that, following the resubmission of its banking licence application in August 2019, the Company has received confirmation from the Prudential Regulation Authority (PRA) that the PRA, with the consent of the Financial Conduct Authority (FCA), has authorised its...
While Watrium refurbish its headquarters at Kanalen 5, Tjuvholmen in Oslo, Norway, the company will temporarily move to its Oslo Atrium office building at Dronning Eufemias gate 6A in Bjørvika in Oslo, from 21 September 2020 to April 2021. Throughout this period, phone number remains the same and business partners should use the following addresses: ...
2019 was an eventful year for Watrium, with several exciting new investments, overall strong development for the portfolio companies, attractive and well positioned real estate assets, and moving into 2020 from a position of strength with a robust balance sheet. The continued value creation from a balanced and diversified investment portfolio, is the result of an investment strategy that Watrium has diligently followed for a long time. Notable business milestones in 2019 includes the investments in HitecVision and CMR Surgical, the listings of Ultimovacs and DF Capital, and the...
Watrium continues its support of Oslo-listed Ultimovacs ASA through participation in a NOK 160 million private placement in the pharmaceutical company. Ultimovacs is developing novel immunotherapies against cancer. The net proceeds of the private placement will secure Ultimovacs' funding of its part of the expected project costs in the new randomized phase II trial to...
CMR Surgical Limited, the Company developing, manufacturing and marketing the next-generation surgical robotic system, Versius®, has raised £195 million ($240 million) to fully fund the global commercialisation of the business.
Ultimovacs is a pharmaceutical company developing novel immunotherapies against cancer. The lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase.
Watrium supports the listing of DF Capital on AIM as cornerstone investor.
Watrium partners with HitecVision by acquiring the interests of the Gjedebo family in HitecVision AS.
Watrium’s portfolio company Flexiteek International, the global leader in synthetic teak decking and the 2G technology, has reached an agreement to acquire Wilks, manufacturer, and supplier of Dek-King synthetic teak decking and marine fendering.
